The immunopathology of experimental visceral leishmaniasis

Immunological Reviews

Volumn 201, Issue , 2004, Pages 239-253

  Kaye, Paul M ^a   Svensson, Mattias ^a   Ato, Manabu ^a   Maroof, Asher ^a   Polley, Rosalind ^a   Stager, Simona ^a   Zubairi, Soombul ^a   Engwerda, Christian R ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; LYMPHOTOXIN; TUMOR NECROSIS FACTOR;

BONE MARROW; CELL COMPARTMENTALIZATION; CELL FUNCTION; CELL LEVEL; CELL MATURATION; CELL SURVIVAL; DENDRITIC CELL; DISEASE ASSOCIATION; DISEASE MODEL; GRANULOMA; HEMATOPOIESIS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFECTION RESISTANCE; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LIVER; LIVER CLEARANCE; LYMPHOID TISSUE; MEMORY CELL; MICROENVIRONMENT; MOUSE STRAIN; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SPLEEN; SPLENOMEGALY; T LYMPHOCYTE; TISSUE GROWTH; TISSUE REACTION; TISSUE REGENERATION; TISSUE STRUCTURE; VISCERAL LEISHMANIASIS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED STRAINS;

EID: 4844219890     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00188.x     Document Type: Review

References (106)

1. Baker R, Chiodini P, Kaye PM. Leishmaniasis. In: Zumla A, James GD, eds. The Granulomatous Diseases. Cambridge, UK: Cambridge University Press, 1999:212-234.
2. Zijlscra EE, el-Hassan AM. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg 2001;95:S27-S58.
3. Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniasis: new approaches to disease control. BMJ 2003;326:377-382.
4. Blackwell JM, et al. SLC11A1 (formerly NRAMP1) and disease resistance. Cell Microbiol 2001;3:773-784.
5. Gruenheid S, Pinner E, Desjardins M, Gros P. Natural resistance to infection with intracellular pathogens: the Nramp1 protein is recruited to the membrane of the phagosome. J Exp Med 1997;185:717-730.
6. Leclercq V, Lebastard M, Belkaid Y, Louis J, Milon G. The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: a tissue-dependent pattern controlled by the Lsh and MHC loci. J Immunol 1996;157:4537-4545.
7. Blackwell JM. The macrophage resistance gene Lsh/Ity/Bcg. Res Immunol 1989;140:767-769.
8. Crocker PR, Blackwell JM, Bradley DJ. Expression of the natural resistance gene Lsh in resident liver macrophages. Infect Immun 1984;43:1033-1040.
9. Vidal S, et al. The Ity/Lsh/Bcg locus: natural resistance to infection with incracellular parasites is abrogated by disruption of the Nramp1 gene. J Exp Med 1995;182:65S-666.
10. Mohamed HS, et al. SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in the Sudan. Eur J Hum Genet 2004;12:66-74.
11. Blackwell JM. Leishmania donovani infection in heterozygous and recombinant H-2 haplotype mice. Immunogenetics 1983;18:101-109.
12. Alexander CE, Kaye PM, Engwerda CR. CD95 is required for the early control of parasite burden in the liver of Leishmania donovani-infected mice. Eur J Immunol 2001;31:1199-1210.
13. Engwerda CR, Kaye PM. Organ-specific immune responses associated with infectious disease. Immunol Today 2000;21:73-78.
14. Kaye PM, Bancroft GJ. Leishmania donovani infection in seid mice: lack of tissue response and in vivo macrophage activation correlates with failure to trigger natural killer cell-derived gamma interferon production in vitro. Infect Immun 1992;60:4335-4342.
15. Murray HW, Stern JJ, Weite K, Rubin BY, Carriero SM, Nathan CF. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol 1987;138:2290-2297.
16. Murray HW, Hariprashad J, Aguero B, Arakawa T, Yeganegi H. Antimicrobial response of a T cell-deficient host to cytokine therapy: effect of interferon-gamma in experimental visceral leishmaniasis in nude mice. J Infect Dis 1995;171:1309-1316.
17. Stern JJ, Oca MJ, Rubin BY, Anderson SL, Murray HW. Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. J Immunol 1988;140:3971-3977.
18. Kaye PM, Curry AJ, Blackwell JM. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 1991;146:2763-2770.
19. Miralles GD, Stoeckle MY, McDermott DF, Finkelman FD, Murray HW. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 1994;62:1058-1063.
20. Murray HW, Nathan CF. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 1999;189:741-746.
21. Smelt SC, Cotterell SE, Engwerda CR, Kaye PM. B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology. J Immunol 2000;164:3681-3688.
22. Cervia JS, Rosen H, Murray HW. Effector role of blood monocytes in experimental visceral leishmaniasis. Infect Immun 1993;61:1330-1333.
23. Gantt KR, et al. Activation of TGF-beta by Leishmania chagasi: importance for parasite survival in macrophages. J Immunol 2003;170:2613-2620.
24. Gomes NA, Gattass CR, Barreto-De-Souza V, Wilson ME, DosReis GA. TGF-beta mediates CTLA-4 suppression of cellular immunity in murine kalaazar. J Immunol 2000;164:2001-2008.
25. Gomes NA, DosReis GA. The dual role of CTLA-4 in Leishmania infection. Trends Parasitol 2001;17:487-491.
26. Murray HW, et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002;70:6284-6293.
27. Murray HW, et al. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J Infect Dis 2003;188:458-464.
28. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP. IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 2001;31:2848-2856.
29. Murray HW. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol 2001;82:249-267.
30. Kaye PM, Engwerda CR. Murine Leishmaniasis. In: Boros D, ed. Granulomatous Inflammation and Infection. Washington DC USA: ASM Press, 2003:117-146.
31. Locksley RM, Scott P. Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. Immunol Today 1991;12:A58-A61.
32. Murray HW, Hariprashad J. Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J Exp Med 1995;181:387-391.
33. Murphy ML, Cotterell SE, Gorak PM, Engwerda CR, Kaye PM. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J Immunol 1998;161:4153-4160.
34. Murphy ML, Engwerda CR, Gorak PM, Kaye PM. B7-2 blockade enhances T cell responses to Leishmania donovani. J Immunol 1997;159:4460-4466.
35. Murray HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL, Heinzel FP. Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect Immun 2003;71:6453-6462.
36. Zubairi S, Sanos S, Hul S, Kaye PM. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur J Immunol 2004;34:1433-1440.
37. Smelt SC, Engwerda CR, McCrossen M, Kaye PM. Destruction of follicular dendritic cells during chronic visceral leishmaniasis. J Immunol 1997;158:3813-3821.
38. Engwerda CR, Murphy ML, Cotterell SE, Smelt SC, Kaye PM. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur J Immunol 1998;28:669-680.
39. Cotterell SE, Engwerda CR, Kaye PM. Enhanced hematopoietic activity accompanies parasite expansion in the spleen and bone marrow of mice infected with Leishmania donovani. Infect Immun 2000;68:1840-1848.
40. Cerami A. Tumor necrosis factor as a mediator of shock, cachexia and inflammation. Blood Purif 1993;11:108-117.
41. Sedgwick JD, Riminton DS, Cyster JG, Korner H. Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol Today 2000;21:110-113.
42. Li C, Sanni LA, Omer F, Riley E, Langhorne J. Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient mice are ameliorated by anti-tumor necrosis factor alpha and exacerbated by anti-transforming growth factor beta antibodies. Infect Immun 2003;71:4850-4856.
43. de Souza JB, Riley EM. Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect 2002;4:291-300.
44. Engwerda CR, Mynott TL, Sawhney S, De Souza JB, Bickle QD, Kaye PM. Locally up-regulated lymphotoxin alpha, not systemic tumor necrosis factor alpha, is the principle mediator of murine cerebral malaria. J Exp Med 2002;195:1371-1377.
45. De Togni P, et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994;264:703-707.
46. Futterer A, Mink K, Luz A, Kosco-Vilbois MH, Pfeffer K. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 1998;9:59-70.
47. Korner H, et al. Distinct roles for lymphotoxin-alpha and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. Eur J Immunol 1997;27:2600-2609.
48. Koni PA, Sacca R, Lawton P, Browning JL, Ruddle NH, Flavell RA. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beudeficient mice. Immunity 1997;6:491-500.
49. Pasparakis M, Alexopoulou L, Grell M, Pfizenmaier K, Bluethmann H, Kollias G. Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. Proc Natl Acad Sci USA 1997;94:6319-6323.
50. Ruuls SR, et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001;15:533-543.
51. Banks TA, et al. Lymphotoxm-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness. J Immunol 1995;155:1685-1693.
52. Mackay F, Majeau GR, Lawton P, Hochman PS, Browning JL. Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice. Eur J Immunol 1997;27:2033-2042.
53. Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003;16:637-646.
54. Roach TI, Barton CH, Chatterjee D, Blackwell JM. Macrophage activation: lipoarabinomannan from avirulent and virulent strains of Mycobacterium tuberculosis differentially induces the early genes c-fos, KC, JE, and tumor necrosis factor-alpha. J Immunol 1993;150:1886-1896.
55. Vazquez MA, et al. Differential regulation of TNF-alpha production by listeriolysin-producing versus nonproducing strains of Listeria monocytogenes. J Leukoc Biol 1995;58:556-562.
56. Belkaid Y, Butcher B, Sacks DL. Analysis of cytokine production by inflammatory mouse macrophages at the single-cell level: selective impairment of IL-12 induction in Leishmania-infected cells. Eur J Immunol 1998;28:1389-1400.
57. Gorak PM, Engwerda CR, Kaye PM. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol 1998;28:687-695.
58. McDowell MA, Sacks DL. Inhibition of host cell signal transducuon by Leishmania: observations relevant to the selective impairment of IL-12 responses. Curr Opin Microbiol 1999;2:438-443.
59. McDowell MA, Marovich M, Lira R, Braun M, Sacks D. Leishmania priming of human dendritic cells for CD40 ligand-induced interleukin-12p70 secretion is strain and species dependent. Infect Immun 2002;70:3994-4001.
60. Chaussabel D, Semnani RT, McDowell MA, Sacks D, Sher A, Nutman TB. Unique gene expression profiles of human macrophages and dendritic cells to phylogenetically distinct parasites. Blood 2003;102:672-681.
61. Carrera L, et al. Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med 1996;183:515-526.
62. Engwerda CR, Smelt SC, Kaye PM. An in vivo analysis of cytokine production during Leishmania donovani infection in seid mice. Exp Parasitol 1996;84:195-202.
63. Tumang MC, et al. Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol 1994;153:768-775.
64. Murray HW, Jungbluth A, Ritter E, Montelibano C, Marino MW. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect Immun 2000;68:6289-6293.
65. Marino MW, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997;94:8093-8098.
66. Annacker O, Asseman C, Read S, Powrie F. Interleukin-10 in the regulation of T cell-induced colitis. J Autoimmun 2003;20:277-279.
67. Fowler S, Powrie F. Control of immune pathology by IL-10-secreting regulatory T cells. Springer Semin Immunopathol 1999;21:287-294.
68. Ato M, Stager S, Engwerda CR, Kaye PM. Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis. Nat Immunol 2002;3:1185-1191.
69. Lucas R, et al. A role for lymphotoxin beta receptor in host defense against Mycobacterium bovis BCG infection. Eur J Immunol 1999;29:4002-4010.
70. Jacobs M, Brown N, Allie N, Ryffel B. Fatal Mycobacterium bovis BCG infection in TNF-LT-alpha-deficient mice. Clin Immunol 2000;94:192-199.
71. Roach DR, Briscoe H, Saunders B, France MP, Riminton S, Britton WJ. Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection. J Exp Med 2001;193:239-246.
72. Bopst M, et al. Differential effects of TNF and LTalpha in the host defense against M. Bovis BCG. Eur J Immunol 2001;31:1935-1943.
73. Cuff CA, Schwartz J, Bergman CM, Russell KS, Bender JR, Ruddle NH. Lymphotoxin alpha3 induces chemokines and adhesion molecules: insight into the role of LT alpha in inflammation and lymphoid organ development. J Immunol 1998;161:6853-6860.
74. Engwerda CR, et al. A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection. Am J Pathol 2002;161:429-437.
75. Kraal G. Cells in the marginal zone of the spleen. Int Rev Cytol 1992;132:31-74.
76. Balazs M, Martin F, Zhou T, Kearney J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 2002;17:341-352.
77. Martin F, Oliver AM, Keamey JF. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 2001;14:617-629.
78. Lyons AB, Parish CR. Are murine marginal-zone macrophages the splenic white pulp analog of high endothelial venules? Eur J Immunol 1995;25:3165-3172.
79. Gunn MD, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999;189:451-460.
80. Nakano H, Mori S, Yonekawa H, Nariuchi H, Matsuzawa A, Kakiuchi T. A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on mouse chromosome 4. Blood 1998;91:2886-2895.
81. Steiniger B, Barth P, Hellinger A. The perifollicular and marginal zones of the human splenic white pulp: do fibroblasts guide lymphocyte immigration? Am J Pathol 2001;159:501-512.
82. Steiniger B, Ruttinger L, Barth PJ. The three-dimensional structure of human splenic white pulp compartments. J Histochem Cytochem 2003;52:655-664.
83. Gommerman JL, Mackay F, Donskoy E, Meier W, Martin P, Browning JL. Manipulation of lymphoid microenvironments in nonhuman primates by an inhibitor of the lymphotoxin pathway. J Clin Invest 2002;110:1359-1369.
84. Kruschinski C, Zidan M, Debertin AS, von Horsten S, Pabst R. Age-dependent development of the splenic marginal zone in human infants is associated with different causes of death. Hum Pathol 2004;35:113-121.
85. Karplus TM, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun 2002;70:6919-6925.
86. Meddeb-Gamaoui A, et al. Association analysis of HLA-class II and class III gene polymorphisms in the susceptibility to Mediterranean visceral leishmaniasis. Hum Immunol 2001;62:509-517.
87. Fernandes Filho JA, Vedeler CA, Myhr KM, Nyland H, Pandey JP. TNF-alpha and - beta gene polymorphisms in multiple sclerosis: a highly significant role for determinants in the first intron of the TNF-beta gene. Autoimmunity 2002;35:377-380.
88. Garrote JA, Arranz E, Telleria JJ, Castro J, Calvo C, Blanco-Quiros A. TNF alpha and LT alpha gene polymorphisms as additional markers of celiac disease susceptibility in a DQ2-positive population. Immunogenetics 2002;54:551-555.
89. Ozaki K, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002;32:650-654.
90. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003;9:1245-1250.
91. Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 2003;62:37-42.
92. Bafica A, Oliveira F, Freitas LA, Nasdmento EG, Barral A. American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifyHine. Int J Dermatol 2003;42:203-207.
93. Cotterell SE, Engwerda CR, Kaye PM. Leishmania donovani infection of bone marrow stromal macrophages selectively enhances myelopoiesis, by a mechanism involving GM-CSF and TNF-alpha. Blood 2000;95:1642-1651.
94. Mirkovich AM, Galelli A, Allison AC, Modabber FZ. Increased myelopoiesis during Leishmania major infection in mice: generation of 'safe targets', a possible way to evade the effector immune mechanism. Clin Exp Immunol 1986;64:1-7.
95. Crocker PR, Davies EV, Blackwell JM. Variable expression of the murine natural resistance gene Lsh in different macrophage populations infected in vitro with Leishmania donovani. Parasite Immunol 1987;9:705-719.
96. Murray HW, Cervia JS, Hariprashad J, Taylor AP, Stoeckle MY, Hockman H. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J Clin Invest 1995;95:1183-1192.
97. Sher A, Pearce E, Kaye P. Shaping the immune response to parasites: role of dendritic cells. Curr Opin Immunol 2003;15:421-429.
98. Reis e Sousa C, Sher A, Kaye P. The role of dendritic cells in the induction and regulation of immunity to microbial infection. Curr Opin Immunol 1999;11:392-399.
99. Wakkach A, Founder N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003;18:605-617.
100. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002;420:502-507.
101. Cillari E, et al. Reduction in the number of UCHL-1+ cells and IL-2 production in the peripheral blood of patients with visceral leishmaniasis. J Immunol 1991;146:1026-1030.
102. Freitas AA, Rocha B. Population biology of lymphocytes: the flight for survival. Annu Rev Immunol 2000;18:83-111.
103. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003;3:269-279.
104. Sprent J, Zhang X, Sun S, Tough D. T-cell turnover in vivo and the role of cytokines. Immunol Lett 1999;65:21-25.
105. Tough DF, Sprent J. Bystander stimulation of T cells in vivo by cytokines. Vet Immunol Immunopathol 1998;63:123-129.
106. Ahmed S, et al. Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect Immun 2003;71:401-410.